# Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

> **NCT05641831** · PHASE2 · RECRUITING · sponsor: **Uma Borate** · enrollment: 110 (estimated)

## Conditions studied

- Clonal Cytopenia of Undetermined Significance

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **DRUG:** Canakinumab
- **PROCEDURE:** Chest Radiography
- **PROCEDURE:** Echocardiography
- **DRUG:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT05641831
- **Lead sponsor:** Uma Borate
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-06
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05641831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05641831, "Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05641831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*